EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study

Kanta Tanaka iD, Kaori Miwa, Masatoshi Koga iD, Sohei Yoshimura, Kenji Kamiyama, Yoshiki Yagita, Yoshinari Nagakane, Haruhiko Hoshino, Tadashi Terasaki, Yasushi Okada, Yusuke Yakushiji, Shinichi Takahashi und 17 weitere

Annals of Neurology · 2024

DOI: 10.1002/ana.26868 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Neurology, 2024. Verfasst von Kanta Tanaka und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. Hauptthemen laut MEDLINE: Cerebral Small Vessel Diseases, Stroke. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to determine the excess risk of antithrombotic‐related bleeding due to cerebral small vessel disease (SVD) burden.

Methods

In this observational, prospective cohort study, patients with cerebrovascular or cardiovascular diseases taking oral antithrombotic agents were enrolled from 52 hospitals across Japan between 2016 and 2019. Baseline multimodal magnetic resonance imaging acquired under prespecified conditions was assessed by a central diagnostic radiology committee to calculate total SVD score. The primary outcome was major bleeding. Secondary outcomes included bleeding at each site and ischemic events.

Results

Of the analyzed 5,250 patients (1,736 women; median age = 73 years, 9,933 patient‐years of follow‐up), antiplatelets and anticoagulants were administered at baseline in 3,948 and 1,565, respectively. Median SVD score was 2 (interquartile range = 1–3). Incidence rate of major bleeding was 0.39 (per 100 patinet‐years) in score 0, 0.56 in score 1, 0.91 in score 2, 1.35 in score 3, and 2.24 in score 4 (adjusted hazard ratio [aHR] for score 4 vs 0 = 5.47, 95% confidence interval [CI] = 2.26–13.23), that of intracranial hemorrhage was 0.11, 0.33, 0.58, 0.99, and 1.06, respectively (aHR = 9.29, 95% CI = 1.99–43.35), and that of ischemic event was 1.82, 2.27, 3.04, 3.91, and 4.07, respectively (aHR = 1.76, 95% CI = 1.08–2.86). In addition, extracranial major bleeding (aHR = 3.43, 95% CI = 1.13–10.38) and gastrointestinal bleeding (aHR = 2.54, 95% CI = 1.02–6.35) significantly increased in SVD score 4 compared to score 0.

Interpretation

Total SVD score was predictive for intracranial hemorrhage and probably for extracranial bleeding, suggesting the broader clinical relevance of cerebral SVD as a marker for safe implementation of antithrombotic therapy. ANN NEUROL 2024;95:774–787

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Small Vessel DiseasesStrokeAgedFemaleHumansAnticoagulantsFibrinolytic AgentsHemorrhageIntracranial HemorrhagesProspective StudiesMale

Substanzen

AnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Japan.
  • Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
  • Department of Neurology, Kyoto Second Red Cross Hospital, Kyoto, Japan.
  • Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Department of Neurology, Kumamoto Red Cross Hospital, Kumamoto, Japan.

ORCID-Profile: Kanta Tanaka, Masatoshi Koga, Masafumi Ihara, Kazunori Toyoda

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research

Zitieren

APA

Tanaka, K., Miwa, K., Koga, M., Yoshimura, S., Kamiyama, K., Yagita, Y., Nagakane, Y., Hoshino, H., Terasaki, T., Okada, Y., Yakushiji, Y., Takahashi, S., Ueda, T., Hasegawa, Y., Shiozawa, M., Sasaki, M., Kudo, K., Tanaka, J., Nishihara, M., …, & Bleeding with Antithrombotic Therapy 2 Investigators (2024). Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study. Annals of Neurology. https://doi.org/10.1002/ana.26868

Vancouver

Tanaka K, Miwa K, Koga M, Yoshimura S, Kamiyama K, Yagita Y, et al. Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study. Annals of Neurology. 2024. doi:10.1002/ana.26868

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Kanta and Miwa, Kaori and Koga, Masatoshi and Yoshimura, Sohei and Kamiyama, Kenji and Yagita, Yoshiki and Nagakane, Yoshinari and Hoshino, Haruhiko and Terasaki, Tadashi and Okada, Yasushi and Yakushiji, Yusuke and Takahashi, Shinichi and Ueda, Toshihiro and Hasegawa, Yasuhiro and Shiozawa, Masayuki and Sasaki, Makoto and Kudo, Kohsuke and Tanaka, Jun and Nishihara, Masashi and Yamaguchi, Yoshitaka and Fujita, Kyohei and Honda, Yuko and Kawano, Hiroyuki and Ide, Toshihiro and Yoshimoto, Takeshi and Ihara, Masafumi and Hirano, Teruyuki and Toyoda, Kazunori and Bleeding with Antithrombotic Therapy 2 Investigators, Bleeding with Antithrombotic Therapy 2 Investigators},
  title = {Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study},
  journal = {Annals of Neurology},
  year = {2024},
  doi = {10.1002/ana.26868}
}
Kostenlos starten →